Latigo Biotherapeutics, a biotechnology company focused on developing non-opioid pain medicines, has filed for an Initial Public Offering (IPO). The company's approach targets the Na V1.8 sodium channel, a key pathway for transmitting pain signals in peripheral nerves. This strategy aligns with a broader industry shift away from opioids due to addiction concerns and regulatory pressures.

Headquartered in Thousand Oaks, California, Latigo was founded by Westlake Village Bio Partners. The company has secured significant venture funding, including a $150 million Series B financing in 2025. Its pipeline includes LTG-001, an oral Na V1.8 inhibitor in Phase II trials for acute pain, and LTG-305, in Phase I trials for chronic pain. These programs aim to offer rapid pain relief without the dependence and safety risks associated with opioids.

Latigo is backed by investors such as Blue Owl Capital, 5AM Ventures, and Foresite Capital. The company's value is closely tied to the clinical success of its Na V1.8 inhibitor programs, with potential to offer alternatives to opioid analgesics in large markets like postoperative pain. Key personnel include CEO Nima Farzan and Chief Medical Officer Neil Singla.